American Century Companies Inc. Purchases 121,764 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

American Century Companies Inc. boosted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 19.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 740,408 shares of the company’s stock after purchasing an additional 121,764 shares during the period. American Century Companies Inc. owned about 1.51% of Amphastar Pharmaceuticals worth $29,616,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. increased its stake in Amphastar Pharmaceuticals by 7.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 379,480 shares of the company’s stock worth $23,471,000 after purchasing an additional 27,102 shares during the period. Epoch Investment Partners Inc. grew its holdings in shares of Amphastar Pharmaceuticals by 348.7% in the fourth quarter. Epoch Investment Partners Inc. now owns 592,530 shares of the company’s stock worth $36,648,000 after purchasing an additional 460,473 shares during the last quarter. TD Asset Management Inc increased its stake in Amphastar Pharmaceuticals by 449.0% in the 4th quarter. TD Asset Management Inc now owns 793,559 shares of the company’s stock worth $49,082,000 after buying an additional 649,001 shares during the period. Silvercrest Asset Management Group LLC lifted its holdings in Amphastar Pharmaceuticals by 35.1% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 112,428 shares of the company’s stock valued at $4,937,000 after buying an additional 29,182 shares in the last quarter. Finally, US Bancorp DE boosted its position in Amphastar Pharmaceuticals by 2,648.8% in the 4th quarter. US Bancorp DE now owns 21,248 shares of the company’s stock valued at $1,314,000 after buying an additional 20,475 shares during the period. 65.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 3,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $46.47, for a total value of $139,410.00. Following the transaction, the director now owns 75,409 shares in the company, valued at $3,504,256.23. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Richard K. Prins sold 17,101 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $43.07, for a total value of $736,540.07. Following the completion of the sale, the director now owns 33,971 shares of the company’s stock, valued at approximately $1,463,130.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Floyd F. Petersen sold 3,000 shares of the company’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $46.47, for a total value of $139,410.00. Following the transaction, the director now directly owns 75,409 shares in the company, valued at $3,504,256.23. The disclosure for this sale can be found here. Insiders sold 37,979 shares of company stock worth $1,671,307 in the last three months. 27.10% of the stock is owned by insiders.

Amphastar Pharmaceuticals Trading Up 2.3 %

NASDAQ:AMPH opened at $49.78 on Thursday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.63 and a current ratio of 3.52. The firm has a 50-day simple moving average of $44.14 and a 200-day simple moving average of $42.60. Amphastar Pharmaceuticals, Inc. has a one year low of $36.56 and a one year high of $65.92. The firm has a market cap of $2.43 billion, a P/E ratio of 17.22, a P/E/G ratio of 0.85 and a beta of 0.82.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.10. The company had revenue of $182.39 million during the quarter, compared to the consensus estimate of $171.29 million. Amphastar Pharmaceuticals had a net margin of 23.36% and a return on equity of 29.79%. Equities analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.71 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. StockNews.com lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, September 12th. Finally, Piper Sandler lowered their target price on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $63.00.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.